National Guideline Clearinghouse | Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab.

National Guideline Clearinghouse | Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab.





National Guideline Clearinghouse Web site maintenance is scheduled for Thursday, February 25, 2016 from 8pm to 12am EST. During this time, the site will be unavailable. We apologize for any inconvenience.

National Institute for Health and Care Excellence (NICE)

• Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab.

Guideline Title

Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab.

Bibliographic Source(s)

National Institute for Health and Care Excellence (NICE). Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab. London (UK): National Institute for Health and Care Excellence (NICE); 2015 Oct 7. 33 p. (Technology appraisal guidance; no. 357).

Guideline Status

This is the current release of the guideline.

This guideline meets NGC's 2013 (revised) inclusion criteria.